董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ann Cunningham | 女 | Director | 58 | 1.67万 | 未持股 | 2026-08-28 |
| Julian Babarczy | 男 | Chairman of the Board and Director | 50 | 89.63万 | 200.00 | 2026-08-28 |
| Lawrence Gozlan | 男 | Director | 47 | 7.50万 | 209.09 | 2026-08-28 |
| Peter A. Marks | 男 | Director | 70 | 7.50万 | 78.01 | 2026-08-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Abby Macnish Niven | 女 | Chief Financial Officer and Company Secretary | 44 | 未披露 | 未持股 | 2026-08-28 |
| David Stamler | 男 | Chief Executive Officer and Managing Director | 65 | 361.18万 | 657.69 | 2026-08-28 |
董事简历
中英对照 | 中文 | 英文- Ann Cunningham
-
Ann Cunningham自2026年4月起担任Alterity Therapeutics Limited集团的董事。她是i3 Strategy Partners的创始人兼首席执行官，i3 Strategy Partners是一家制药咨询集团，专注于通过创新的患者参与策略改善健康结果，特别是在服务欠缺的社区。坎宁安女士指导高级制药和生物技术主管规划和执行多个成功的投资组合战略和重磅品牌发布。Cunningham女士还担任梯瓦制药神经退行性疾病和精神病学副总裁，领导了产品组合的商业开发。她目前在Vistagen Therapeutics董事会任职，此前曾担任其首席商务官。Cunningham女士拥有耶鲁大学心理学学士学位和密歇根大学Stephen M. Ross商学院MBA学位。
Ann Cunningham has served as a director of Alterity Therapeutics Limited's Group since April 2026.She is the Founder and Chief Executive Officer of i3 Strategy Partners, a pharmaceutical consulting group focused on improving health outcomes through innovative patient engagement strategies, particularly within underserved communities. Ms. Cunningham has guided senior pharmaceutical and biotechnology executives in planning and executing multiple successful portfolio strategies and blockbuster brand launches. Ms. Cunningham also led the commercial development of a product portfolio as Vice President of Neurodegenerative Disease and Psychiatry at Teva Pharmaceutical Industries. She currently serves on the Board of Directors of Vistagen Therapeutics and previously served as its Chief Commercial Officer. Ms. Cunningham holds a B.A. in Psychology from Yale University and an MBA from the University of Michigan, Stephen M. Ross School of Business. - Ann Cunningham自2026年4月起担任Alterity Therapeutics Limited集团的董事。她是i3 Strategy Partners的创始人兼首席执行官，i3 Strategy Partners是一家制药咨询集团，专注于通过创新的患者参与策略改善健康结果，特别是在服务欠缺的社区。坎宁安女士指导高级制药和生物技术主管规划和执行多个成功的投资组合战略和重磅品牌发布。Cunningham女士还担任梯瓦制药神经退行性疾病和精神病学副总裁，领导了产品组合的商业开发。她目前在Vistagen Therapeutics董事会任职，此前曾担任其首席商务官。Cunningham女士拥有耶鲁大学心理学学士学位和密歇根大学Stephen M. Ross商学院MBA学位。
- Ann Cunningham has served as a director of Alterity Therapeutics Limited's Group since April 2026.She is the Founder and Chief Executive Officer of i3 Strategy Partners, a pharmaceutical consulting group focused on improving health outcomes through innovative patient engagement strategies, particularly within underserved communities. Ms. Cunningham has guided senior pharmaceutical and biotechnology executives in planning and executing multiple successful portfolio strategies and blockbuster brand launches. Ms. Cunningham also led the commercial development of a product portfolio as Vice President of Neurodegenerative Disease and Psychiatry at Teva Pharmaceutical Industries. She currently serves on the Board of Directors of Vistagen Therapeutics and previously served as its Chief Commercial Officer. Ms. Cunningham holds a B.A. in Psychology from Yale University and an MBA from the University of Michigan, Stephen M. Ross School of Business.
- Julian Babarczy
-
Julian Babarczy自2025年11月起担任Alterity Therapeutics Limited集团董事长。朱利安是一位经验丰富的投资主管和公司董事，在澳大利亚金融市场拥有超过25年的经验。他在Regal Partners担任了十多年的高级领导职务，为该公司从一家精品基金经理成长为一家价值数十亿美元的投资公司做出了贡献，在那里他领导或贡献了一系列跨越广泛领域的投资组合。自2020年以来，朱利安专注于董事会领导和战略顾问角色，支持科技、金融服务、自然资源和其他创新引领行业的高增长公司。他拥有重要的资本市场专业知识、强大的治理能力以及帮助公司在运营和地域上扩大规模的亲力亲为的方法。朱利安是CFA特许持有人，拥有莫纳什大学商学学士学位。
Julian Babarczy has served as Chairman of Alterity Therapeutics Limited's Group since November 2025. Julian is an experienced investment executive and company director with over 25 years of experience in Australia's financial markets. He spent over a decade in senior leadership roles at Regal Partners, contributing to the firm's growth from a boutique fund manager to a multi billion dollar investment house, where he led or contributed to a range of investment portfolios spanning a wide range of sectors. Since 2020, Julian has focused on board leadership and strategic advisory roles, supporting high growth companies in technology, financial services, natural resources and other innovation led industries. He possesses significant capital markets expertise, strong governance capabilities and a hands on approach to assisting companies to scale both operationally and geographically. Julian is a CFA Charterholder and holds a Bachelor of Business from Monash University. - Julian Babarczy自2025年11月起担任Alterity Therapeutics Limited集团董事长。朱利安是一位经验丰富的投资主管和公司董事，在澳大利亚金融市场拥有超过25年的经验。他在Regal Partners担任了十多年的高级领导职务，为该公司从一家精品基金经理成长为一家价值数十亿美元的投资公司做出了贡献，在那里他领导或贡献了一系列跨越广泛领域的投资组合。自2020年以来，朱利安专注于董事会领导和战略顾问角色，支持科技、金融服务、自然资源和其他创新引领行业的高增长公司。他拥有重要的资本市场专业知识、强大的治理能力以及帮助公司在运营和地域上扩大规模的亲力亲为的方法。朱利安是CFA特许持有人，拥有莫纳什大学商学学士学位。
- Julian Babarczy has served as Chairman of Alterity Therapeutics Limited's Group since November 2025. Julian is an experienced investment executive and company director with over 25 years of experience in Australia's financial markets. He spent over a decade in senior leadership roles at Regal Partners, contributing to the firm's growth from a boutique fund manager to a multi billion dollar investment house, where he led or contributed to a range of investment portfolios spanning a wide range of sectors. Since 2020, Julian has focused on board leadership and strategic advisory roles, supporting high growth companies in technology, financial services, natural resources and other innovation led industries. He possesses significant capital markets expertise, strong governance capabilities and a hands on approach to assisting companies to scale both operationally and geographically. Julian is a CFA Charterholder and holds a Bachelor of Business from Monash University.
- Lawrence Gozlan
-
Lawrence Gozlan， 2011年8月8日，他被任命为Opthea Limited董事。他是一流的生物技术投资人和顾问，是Scientia Capital的首席投资官和创始人， 该公司是专门从事生命科学的专业全球投资基金。公司成立是为想要进军生物技术业的个人、家族办事处和机构投资者提供高层次知识和管理高净值投资。在此之前，他曾负责澳大利亚最大的生物技术投资组合，担任QIC的生物技术分析师，该公司是投资基金，管理总值超过600亿澳元。他曾担任Foster Stockbroking Pty Ltd的股票团队的高级生物技术分析师，在德勒（Deloitte）为生命科学公司提供咨询服务获得高级公司财政经验。他还是在澳大利亚证交所（ASX）上市的Oncosil Medical ASX：OSL和Phosphagenics （ASX：POH）的董事。他在Melbourne大学获得荣誉微生物学和免疫学学士学位，专门研究神经退行性疾病。
Lawrence Gozlan has served as a director of Alterity Therapeutics Limited's Group since August 2011. Mr. Gozlan, a leading biotechnology investor and advisor, is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. Scientia Capital was founded to provide high level expertise and to manage investments for high net worth individuals, family offices and institutional investors wanting exposure to the biotechnology industry. Prior to this, Mr. Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC ("the Queensland Investment Corporation"), an investment fund with over A$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd and gained senior corporate finance experience advising life sciences companies at Deloitte. Mr. Gozlan is currently a Director of Ceryvyn Therapeutics Limited, (ASX:CYV) and Enlitic Inc, (ASX:ENL). He holds a Bachelor of Science with Honors in microbiology and immunology from the University of Melbourne. - Lawrence Gozlan， 2011年8月8日，他被任命为Opthea Limited董事。他是一流的生物技术投资人和顾问，是Scientia Capital的首席投资官和创始人， 该公司是专门从事生命科学的专业全球投资基金。公司成立是为想要进军生物技术业的个人、家族办事处和机构投资者提供高层次知识和管理高净值投资。在此之前，他曾负责澳大利亚最大的生物技术投资组合，担任QIC的生物技术分析师，该公司是投资基金，管理总值超过600亿澳元。他曾担任Foster Stockbroking Pty Ltd的股票团队的高级生物技术分析师，在德勒（Deloitte）为生命科学公司提供咨询服务获得高级公司财政经验。他还是在澳大利亚证交所（ASX）上市的Oncosil Medical ASX：OSL和Phosphagenics （ASX：POH）的董事。他在Melbourne大学获得荣誉微生物学和免疫学学士学位，专门研究神经退行性疾病。
- Lawrence Gozlan has served as a director of Alterity Therapeutics Limited's Group since August 2011. Mr. Gozlan, a leading biotechnology investor and advisor, is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. Scientia Capital was founded to provide high level expertise and to manage investments for high net worth individuals, family offices and institutional investors wanting exposure to the biotechnology industry. Prior to this, Mr. Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC ("the Queensland Investment Corporation"), an investment fund with over A$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd and gained senior corporate finance experience advising life sciences companies at Deloitte. Mr. Gozlan is currently a Director of Ceryvyn Therapeutics Limited, (ASX:CYV) and Enlitic Inc, (ASX:ENL). He holds a Bachelor of Science with Honors in microbiology and immunology from the University of Melbourne.
- Peter A. Marks
-
Peter A. Marks，自2005年7月起担任集团董事。Peter在企业咨询和投资银行方面拥有超过35年的经验。在其漫长的职业生涯中，他专门为澳大利亚、美国和以色列的公司进行融资、IPO、跨境、并购交易、企业承销和风险投资交易。他参与了广泛的交易，特别关注生命科学、生物技术、医疗技术和高科技领域。Marks先生于2020年1月至2021年10月期间在Elsight Limited（ASX：ELS）董事会担任董事，于2020年1月至2022年8月期间在Nyrada Inc.（ASX：NYR）董事会担任董事，目前在Noxopharm Limited（ASX：NOX）（2016年3月任命）、Iris Metals Limited（ASX：IR1）（2020年12月任命）和Evergreen Lithium Limited（TERM0：EG1）（2022年1月任命）担任董事会成员。Marks先生拥有工商管理硕士学位、经济学学士学位、法学学士学位和商法研究生学位的经验和专长。
Peter A. Marks has served as a director of Alterity Therapeutics Limited's Group since July 2005. Peter has over 35 years' experience in corporate advisory and investment banking. Over the course of his long career, he has specialised in capital raisings, IPOs, cross border, M&A transactions, corporate underwriting and venture capital transactions for companies in Australia, the United States and Israel. He has been involved in a broad range of transactions with a special focus in the life sciences, biotechnology, medical technology and high tech segments. Mr. Marks served as a director on the Board of Elsight Limited (ASX:ELS) between January 2020 and October 2021, on the Board of Nyrada Inc. (ASX:NYR) between January 2020 and August 2022, and currently serves on the Board of Noxopharm Limited (ASX:NOX) (appointed in March 2016), Iris Metals Limited (ASX:IR1) (appointed in December 2020), and EverGreen Lithium Limited (ASX:EG1) (appointed in January 2022). Mr. Marks has an MBA, Bachelor of Economics, Bachelor of Law, and Grad Dip in Commercial Law. - Peter A. Marks，自2005年7月起担任集团董事。Peter在企业咨询和投资银行方面拥有超过35年的经验。在其漫长的职业生涯中，他专门为澳大利亚、美国和以色列的公司进行融资、IPO、跨境、并购交易、企业承销和风险投资交易。他参与了广泛的交易，特别关注生命科学、生物技术、医疗技术和高科技领域。Marks先生于2020年1月至2021年10月期间在Elsight Limited（ASX：ELS）董事会担任董事，于2020年1月至2022年8月期间在Nyrada Inc.（ASX：NYR）董事会担任董事，目前在Noxopharm Limited（ASX：NOX）（2016年3月任命）、Iris Metals Limited（ASX：IR1）（2020年12月任命）和Evergreen Lithium Limited（TERM0：EG1）（2022年1月任命）担任董事会成员。Marks先生拥有工商管理硕士学位、经济学学士学位、法学学士学位和商法研究生学位的经验和专长。
- Peter A. Marks has served as a director of Alterity Therapeutics Limited's Group since July 2005. Peter has over 35 years' experience in corporate advisory and investment banking. Over the course of his long career, he has specialised in capital raisings, IPOs, cross border, M&A transactions, corporate underwriting and venture capital transactions for companies in Australia, the United States and Israel. He has been involved in a broad range of transactions with a special focus in the life sciences, biotechnology, medical technology and high tech segments. Mr. Marks served as a director on the Board of Elsight Limited (ASX:ELS) between January 2020 and October 2021, on the Board of Nyrada Inc. (ASX:NYR) between January 2020 and August 2022, and currently serves on the Board of Noxopharm Limited (ASX:NOX) (appointed in March 2016), Iris Metals Limited (ASX:IR1) (appointed in December 2020), and EverGreen Lithium Limited (ASX:EG1) (appointed in January 2022). Mr. Marks has an MBA, Bachelor of Economics, Bachelor of Law, and Grad Dip in Commercial Law.
高管简历
中英对照 | 中文 | 英文- Abby Macnish Niven
Abby Macnish Niven于2024年9月被任命为Alterity Therapeutics Limited集团的首席财务官，并于2024年11月被任命为公司秘书。Macnish Niven女士是一名特许金融分析师，拥有西澳大利亚大学商学学士和理学学士学位。她在ANZ、UBS、Ord Minnett等集团拥有丰富的私人财富管理经验，并在治理、财务和公司结构方面为一系列上市和非上市公司提供咨询。
Abby Macnish Niven was appointed as Chief Financial Officer for Alterity Therapeutics Limited's Group in September 2024 and as Company Secretary in November 2024. Ms. Macnish Niven is a Chartered Financial Analyst and holds a Bachelor of Commerce and a Bachelor of Science degree from the University of Western Australia. She has extensive experience in private wealth management with groups including ANZ, UBS, and Ord Minnett, and consults to a range of listed and unlisted companies in governance, finance, and corporate structure.- Abby Macnish Niven于2024年9月被任命为Alterity Therapeutics Limited集团的首席财务官，并于2024年11月被任命为公司秘书。Macnish Niven女士是一名特许金融分析师，拥有西澳大利亚大学商学学士和理学学士学位。她在ANZ、UBS、Ord Minnett等集团拥有丰富的私人财富管理经验，并在治理、财务和公司结构方面为一系列上市和非上市公司提供咨询。
- Abby Macnish Niven was appointed as Chief Financial Officer for Alterity Therapeutics Limited's Group in September 2024 and as Company Secretary in November 2024. Ms. Macnish Niven is a Chartered Financial Analyst and holds a Bachelor of Commerce and a Bachelor of Science degree from the University of Western Australia. She has extensive experience in private wealth management with groups including ANZ, UBS, and Ord Minnett, and consults to a range of listed and unlisted companies in governance, finance, and corporate structure.
- David Stamler
David Stamler于2008年至2010年在上市的生物制药公司XenoPort生物制药公司担任高级副总裁兼首席医疗官，于2005年至2008年在私营制药公司Prestwick Pharmaceuticals，Inc.担任首席科学官兼药物开发主管。在加入Prestwick Pharmaceuticals，Inc.之前，Stamler博士曾于1997年至2005年在Fujisawa Pharmaceutical Co.及其子公司担任各种领导职务，包括2003年至2005年在Fujisawa Healthcare，Inc.担任医学科学研究与发展副总裁，以及2000年至2003年在美国藤泽研究所担任临床研究中心副总裁。Stamler博士的职业生涯始于雅培，这是一家全球药品和医疗保健产品上市公司，他曾于1993年至1997年担任多个职位，包括国际分部药品产品临床研究总监。Stamler博士获得了芝加哥大学-普利兹克医学院的医学博士学位和芝加哥大学的生物学学士学位。
David Stamler served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., a publicly-traded biopharmaceutical company, from 2008 to 2010 and Chief Scientific Officer and Head of Drug Development at Prestwick Pharmaceuticals, Inc., a private pharmaceutical company, from 2005 to 2008. Prior to Prestwick Pharmaceuticals, Inc., Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries from 1997 to 2005 in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc. from 2003 to 2005 and as Vice President, Clinical Research Center at Fujisawa Research Institute of America from 2000 to 2003. Dr. Stamler began his career at Abbott Laboratories, a publicly-traded global pharmaceuticals and healthcare products company, where he served in various positions from 1993 to 1997 including Director of Clinical Research, Pharmaceutical Products for the International Division. Dr. Stamler received an M.D. from the University of Chicago-The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.- David Stamler于2008年至2010年在上市的生物制药公司XenoPort生物制药公司担任高级副总裁兼首席医疗官，于2005年至2008年在私营制药公司Prestwick Pharmaceuticals，Inc.担任首席科学官兼药物开发主管。在加入Prestwick Pharmaceuticals，Inc.之前，Stamler博士曾于1997年至2005年在Fujisawa Pharmaceutical Co.及其子公司担任各种领导职务，包括2003年至2005年在Fujisawa Healthcare，Inc.担任医学科学研究与发展副总裁，以及2000年至2003年在美国藤泽研究所担任临床研究中心副总裁。Stamler博士的职业生涯始于雅培，这是一家全球药品和医疗保健产品上市公司，他曾于1993年至1997年担任多个职位，包括国际分部药品产品临床研究总监。Stamler博士获得了芝加哥大学-普利兹克医学院的医学博士学位和芝加哥大学的生物学学士学位。
- David Stamler served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., a publicly-traded biopharmaceutical company, from 2008 to 2010 and Chief Scientific Officer and Head of Drug Development at Prestwick Pharmaceuticals, Inc., a private pharmaceutical company, from 2005 to 2008. Prior to Prestwick Pharmaceuticals, Inc., Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries from 1997 to 2005 in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc. from 2003 to 2005 and as Vice President, Clinical Research Center at Fujisawa Research Institute of America from 2000 to 2003. Dr. Stamler began his career at Abbott Laboratories, a publicly-traded global pharmaceuticals and healthcare products company, where he served in various positions from 1993 to 1997 including Director of Clinical Research, Pharmaceutical Products for the International Division. Dr. Stamler received an M.D. from the University of Chicago-The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.